Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis

a technology of nucleotide vectors and compositions, applied in the direction of immunological disorders, antibody medical ingredients, peptide sources, etc., can solve the problems of time-consuming and expensive production and maintenance of these vaccines, widespread and serious international health problems, and inability to mass immunization

Inactive Publication Date: 2011-02-03
INST PASTEUR +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hepatitis B is a widespread and serious international health problem.
While this vaccine was effective, mass immunization was not feasible due to the long and expensive purification procedure, the need to assay each batch on chimpanzees for safety, and the limited supply of chronically infected human plasma (Maugh, Science 210:760-762 (1980); Stephenne, Vaccine 6:299-303 (1988)).
While the present protein vaccines are highly effective and safe, the production and maintenance of these vaccines is time-consuming and expensive (Davis, 1993).
On the other hand, the production of a viral vaccine is not feasible due to safety considerations.
However, the authors specify that this method is not practical.
The DNA-based vaccines suggested by the prior art have not been capable of practical uses.
This type of treatment can not be considered for human vaccination due to the safety risks involved for the patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
  • Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
  • Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Induction of Antibodies Against a Hepatitis B Surface Antigen by Sequential Injection of Bupivacaine and of a Plasmid Carrying a Gene Coding for the Antigen

[0094](1) Materials and Methods

[0095]1.1 Bupivacaine Pretreatment

[0096]All experiments were made on the muscles of the anterior tibia (AT) of mice C57BL / 6 aged between 5 to 7 weeks.

[0097]A single degeneration-regeneration cycle of the muscle fibers is induced in the muscles of the anterior tibia of non-anaesthetized mice, by intramuscular injection of 50 μl marcaine (bupivacaine 0.5%, DMSO 1%) sold by Laboratoires Astra, France. The solution is injected using a tuberculosis syringe with a needle fitted into a polyethylene sleeve in order to limit the penetration depth to 2 mm.

[0098]As marcaine is an anesthetic, injections into the right and left legs were performed at 10 to 30 minute intervals to prevent an overdose.

[0099]1.2 DNA Preparation

[0100]The plasmid used was constructed by cloning into a modified pBlueScript vector of th...

example 2

Comparison of the Efficiency of a Plasmid Injection in the Presence and Absence of Lipids

[0116]A dose of 10 μg plasmid DNA from the SV40-luciferase vector available commercially (“pGL2-Control Vector” from Promega, reference E1 11) in 50 μl of physiological solution was injected into the sucrose pretreated muscle following the method of Davis et al. (Hum. Gene Ther. 4:151-159 (1993)). The injected DNA is mixed earlier with lipids such as dioctadecylamidoglycyl spermine (DOGS) or the following mixtures: DOGS+spermidine, and DOGS+polyethyleneglycol (PEG). The luciferase activity was determined 5 days after the injection.

[0117]These results are shown in table II below.

[0118]They show that the presence of lipids (DOGS) very significantly reduces the efficiency of the plasmid injection with respect to a composition with no lipids (Control).

example 3

Comparison of the Responses of Mice and Rabbits to Plasmids Carrying Different Promoters and Envelope Genes for the HBV Virus

[0119]Five plasmids were constructed allowing the expression of one, two, or three envelope proteins for the HBV virus. In three of the constructions (pCMVHB-S, pCMVHB-S2.S, pCMVHB-S1.S2.S) the genes coding for the HBV virus envelope proteins are put under transcriptional control of the promoter of the CMV virus precursor genes (FIG. 1, FIG. 2A to 2C, FIGS. 3 and 4). The fourth plasmid (pHBV-S1.S2.S) uses the promoter for the HBV virus surface genes contained in the pre-S1 region of this virus (Cattaneo et al. (1983) Nature, 305, 336) (FIG. 2D) as a transcriptional controlling element. In another plasmid, pSVS, the three envelope proteins were placed under control of the SV40 promoter (pSVS) (Michel et al., Proc. Natl. Acad. Sci. USA, 81:7708-7712 (1984)). The construction of the pSVS plasmid is further described in EP0 156 712 B1. In the five constructions, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
penetration depthaaaaaaaaaa
areaaaaaaaaaaa
optical densityaaaaaaaaaa
Login to view more

Abstract

Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of application Ser. No. 08 / 706,337, filed Aug. 30, 1996, which is a continuation-in-part of application Ser. No. 08 / 633,821, filed Apr. 22, 1996, which is based on International Application PCT / FR94 / 00483, filed Apr. 27, 1994. The entire disclosure of each of these applications is relied upon and incorporated by reference herein.BACKGROUND OF THE INVENTION[0002]The present invention relates to compositions for inducing protective antibodies against hepatitis. It also relates to a vector comprising a nucleotide sequence coding for at least a portion of a virus protein, which is capable of being expressed in muscle cells. In addition, the invention relates to compositions capable of inducing a T cell response in chronic HBV carriers.[0003]Hepatitis B is a widespread and serious international health problem. In addition to causing acute hepatitis and liver damage, the hepatitis B virus (HBV) can cau...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/29C12N15/63A61K39/00A61K31/7088A61P37/04A61P31/20A61K48/00C07K14/02
CPCA61K39/00A61K39/292A61K48/00C12N2730/10134C07K14/005C12N2730/10122A61K2039/53A61K39/12A61K2039/545A61K2039/55566A61K2039/575A61P31/20A61P37/04
Inventor MICHEL, MARIE-LOUISEMANCINI, MARYLINE
Owner INST PASTEUR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap